Re: EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-Specific and Overall Survival in Non-Muscle-Invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin Editorial Comment

被引：3
|
作者：
Chang, Sam S.
机构：
来源：
JOURNAL OF UROLOGY | 2017年 / 198卷 / 01期
关键词：
D O I：
10.1016/j.juro.2017.04.004
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：39 / 40
页数：2
相关论文
共 35 条
  • [1] EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin
    Cambier, Samantha
    Sylvester, Richard J.
    Collette, Laurence
    Gontero, Paolo
    Brausi, Maurizio A.
    van Andel, George
    Kirkels, Wim J.
    Da Silva, Fernando Calais
    Oosterlinck, Willem
    Prescott, Stephen
    Kirkali, Ziya
    Powell, Philip H.
    de Reijke, Theo M.
    Turkeri, Levent
    Collette, Sandra
    Oddens, Jorg
    EUROPEAN UROLOGY, 2016, 69 (01) : 60 - 69
  • [2] Re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin. Eur Urol 2016;69:60-9
    Williams, Stephen B.
    Kamat, Ashish M.
    EUROPEAN UROLOGY, 2016, 69 (06) : E121 - E122
  • [3] The EORTC Tables Overestimate the Risk of Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin: External Validation of the EORTC Risk Tables
    Fernandez-Gomez, Jesus
    Madero, Rosario
    Solsona, Eduardo
    Unda, Miguel
    Martinez-Pineiro, Luis
    Ojea, Antonio
    Portillo, Jose
    Montesinos, Manuel
    Gonzalez, Marcelino
    Pertusa, Carlos
    Rodriguez-Molina, Jesus
    Emilio Camacho, Jose
    Rabadan, Mariano
    Astobieta, Ander
    Isorna, Santiago
    Muntanola, Pedro
    Gimeno, Anabel
    Blas, Miguel
    Antonio Martinez-Pineiro, Jose
    EUROPEAN UROLOGY, 2011, 60 (03) : 423 - 430
  • [4] Reply to Stephen B. Williams and Ashish M. Kamat's Letter to the Editor re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin. Eur Urol 2016;69:60-9
    Sylvester, Richard
    Gontero, Paolo
    Oddens, Jorg
    EUROPEAN UROLOGY, 2016, 69 (06) : E123 - E124
  • [5] The updated EAU prognostic factor risk groups overestimate the risk of progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin
    Lobo, N.
    Hensley, P. J.
    Bree, K. K.
    Nogueras-Gonzalez, G. M.
    Navai, N.
    Dinney, C. P.
    Sylvester, R. J.
    Kamat, A. M.
    EUROPEAN UROLOGY, 2022, 81 : S229 - S229
  • [6] Re: Prognostic Factors and Risk Groups in T1G3 Non-Muscle-Invasive Bladder Cancer Patients Initially Treated with bacillus Calmette-Guerin: Results of a Retrospective Multicenter Study of 2451 Patients
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2016, 195 (05): : 1382 - 1382
  • [7] Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guerin
    Lobo, Niyati
    Hensley, Patrick J.
    Bree, Kelly K.
    Nogueras-Gonzalez, Graciela M.
    Navai, Neema
    Dinney, Colin P.
    Sylvester, Richard J.
    Kamat, Ashish M.
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (01): : 84 - 91
  • [8] Re: Contemporary Cost-Effectiveness Analysis Comparing Sequential bacillus Calmette-Guerin and Electromotive Mitomycin versus bacillus Calmette-Guerin Alone for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer Editorial Comment
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2015, 194 (03): : 666 - 666
  • [9] Prognostic Factors and Risk Groups in T1G3 Non-Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guerin: Results of a Retrospective Multicenter Study of 2451 Patients
    Gontero, Paolo
    Sylvester, Richard
    Pisano, Francesca
    Joniau, Steven
    Eeckt, Kathy Vander
    Serretta, Vincenzo
    Larre, Stephane
    Di Stasi, Savino
    Van Rhijn, Bas
    Witjes, Alfred J.
    Grotenhuis, Anne J.
    Kiemeney, Lambertus A.
    Colombo, Renzo
    Briganti, Alberto
    Babjuk, Marek
    Malmstrom, Per-Uno
    Oderda, Marco
    Irani, Jacques
    Malats, Nuria
    Baniel, Jack
    Mano, Roy
    Cai, Tommaso
    Cha, Eugene K.
    Ardelt, Peter
    Varkarakis, John
    Bartoletti, Riccardo
    Spahn, Martin
    Johansson, Robert
    Frea, Bruno
    Soukup, Viktor
    Xylinas, Evanguelos
    Dalbagni, Guido
    Karnes, R. Jeffrey
    Shariat, Shahrokh F.
    Palou, Joan
    EUROPEAN UROLOGY, 2015, 67 (01) : 74 - 82
  • [10] Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guerin
    Baltaci, Sumer
    Bozlu, Murat
    Yildirim, Asif
    Gokce, Mehmet Ilker
    Tinay, Ilker
    Aslan, Guven
    Can, Cavit
    Turkeri, Levent
    Kuyumcuoglu, Ugur
    Mungan, Aydin
    BJU INTERNATIONAL, 2015, 116 (05) : 721 - 726
1234